Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Accumulated Expenses data on record, last reported at $17.9 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 25.22% year-over-year to $17.9 million; the TTM value through Dec 2025 reached $17.9 million, down 25.22%, while the annual FY2025 figure was $17.9 million, 25.22% down from the prior year.
  • Accumulated Expenses reached $17.9 million in Q4 2025 per AMLX's latest filing, down from $19.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $67.9 million in Q1 2024 and bottomed at $3.6 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $30.5 million, with a median of $23.9 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: surged 982.18% in 2023, then tumbled 82.22% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $4.3 million in 2021, then soared by 795.14% to $38.3 million in 2022, then skyrocketed by 50.67% to $57.7 million in 2023, then tumbled by 58.51% to $23.9 million in 2024, then fell by 25.22% to $17.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $17.9 million in Q4 2025, $19.5 million in Q3 2025, and $17.5 million in Q2 2025.